PACS Group, Inc.

PACS Group, Inc. (PACS) Market Cap

PACS Group, Inc. has a market capitalization of $5.53B.

Financials based on reported quarter end 2025-12-31

Price: $35.20

0.88 (2.55%)

Market Cap: 5.53B

NYSE · time unavailable

CEO: Jason Murray

Sector: Financial Services

Industry: Financial - Conglomerates

IPO Date: 2024-04-11

Website: https://pacs.com

PACS Group, Inc. (PACS) - Company Information

Market Cap: 5.53B · Sector: Financial Services

PACS Group, Inc. is a holding company, which engages in the provision of post-acute healthcare facilities, professionals, and ancillary services. It provides senior care, assisted living, and independent living options in some of the communities. The company was founded by Jason Murray and Mark Hancock in 2013 and is headquartered in Farmington, UT.

Analyst Sentiment

89%
Strong Buy

Based on 6 ratings

Analyst 1Y Forecast: $42.80

Average target (based on 2 sources)

Consensus Price Target

Low

$40

Median

$42

High

$52

Average

$45

Potential Upside: 26.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PACS GROUP INC (PACS) — Investment Overview

🧩 Business Model Overview

PACS Group Inc operates in the healthcare services ecosystem by providing clinical and administrative technology-enabled services to care delivery organizations. The model is built around integrating PACS’ offerings into provider workflows—typically involving patient access, care navigation, and digital/operational services that reduce friction for both patients and clinicians.

Value creation is driven by (1) onboarding provider customers into a repeatable service workflow, (2) sustaining performance through ongoing service delivery and operational support, and (3) expanding account-level usage through additional capabilities once systems and processes are embedded. This creates a “land-and-expand” dynamic where the first contract reduces friction for future work within the same network of stakeholders (patients, providers, and downstream care teams).

💰 Revenue Streams & Monetisation Model

Monetisation is generally structured around a mix of service fees and technology/operations-related revenue streams that scale with patient volumes, care episodes, or utilization-based performance metrics. Over time, the revenue profile tends to include a higher proportion of recurring components as provider customers rely on established systems and service processes rather than re-procuring from scratch.

Margin drivers typically include: (1) utilization and throughput improvements in service operations, (2) economies of scale in administrative and platform-related costs, and (3) disciplined customer onboarding that improves payback periods. Competitive differentiation often manifests in execution quality and reliability, which supports renewal rates and reduces churn-related revenue volatility.

🧠 Competitive Advantages & Market Positioning

Primary moat: switching costs and workflow integration.

Once a provider integrates PACS’ services into daily operations—covering staffing workflows, operational routing, patient communication, and data/reporting routines—switching becomes costly. Switching costs arise from process redesign, staff retraining, clinical/administrative revalidation, and the risk of service disruption to patient throughput. These frictions make customer migration slower and less frequent than in purely transactional businesses.

Secondary moat: know-how and execution quality (intangible/operational asset).

Operational playbooks, service delivery know-how, and relationship networks with healthcare stakeholders create an intangible advantage that is difficult to replicate quickly. Competitors can offer similar features, but replicating consistent performance under healthcare operational constraints typically requires time and proven delivery.

Limited direct “network effects” but meaningful ecosystem embedment.

Network effects are not always the central driver; however, deeper embedment within provider ecosystems can create indirect benefits—data and process learnings improve service delivery, and better outcomes reinforce continued usage. This sustains account-level demand and improves the economics of renewals.

🚀 Multi-Year Growth Drivers

1) Secular digitization of healthcare operations. Healthcare providers continue shifting toward data-enabled workflows to improve operational efficiency, patient access, and care coordination. Technology-enabled services that reduce administrative burden and improve throughput remain structurally in demand.

2) Continued expansion of patient access and navigation needs. System complexity (scheduling bottlenecks, care pathways, and coordination requirements) creates long-duration demand for services that streamline patient journeys. This supports steady utilization-based revenue and provides a platform for additional service modules over time.

3) Provider consolidation and standardization. As health systems consolidate, standardized service delivery becomes more important. Vendors with repeatable implementations and proven operational controls can win share when centralized procurement expands usage across broader footprints.

4) TAM expansion through account-level “share of wallet.” The growth path often involves increasing penetration within existing customer relationships—adding capabilities, expanding service coverage, and improving usage intensity—rather than relying exclusively on new logo acquisition.

⚠ Risk Factors to Monitor

Contract concentration and renewal risk: Revenue durability depends on maintaining renewals and expanding existing accounts. Any slowdown in provider spending or adverse contract terms can impact growth and margins.

Regulatory and compliance burden: Healthcare services face evolving privacy, security, reimbursement, and reporting requirements. Non-compliance or increased cost of compliance can pressure profitability.

Technology and platform disruption: Competitors may introduce functionally similar offerings or automate parts of workflows, potentially reducing differentiation. PACS’ resilience depends on continuing execution quality and maintaining embedded workflows that increase switching costs.

Operational execution risk: Service delivery quality, staffing constraints, and performance consistency are critical in healthcare operations. Quality lapses can lead to slower expansions or customer churn.

Capital intensity and investment needs: Scaling service delivery and technology capabilities can require upfront investment. Returns depend on achieving sufficient utilization, reducing unit costs, and sustaining long-term customer value.

📊 Valuation & Market View

The market typically values healthcare services and technology-enabled service providers using EV/EBITDA (or EV/Revenue for earlier-stage or margin-volatile models) while placing emphasis on: (1) revenue quality (recurrence vs. transactional dependence), (2) operating leverage potential, and (3) evidence of durable retention and account expansion.

Key valuation drivers generally include sustained margins through scale, stable cash generation, improving unit economics, and credible growth in provider utilization. Persistent margin compression or weaker retention tends to drive de-rating due to the perception of limited operating leverage.

🔍 Investment Takeaway

PACS Group Inc offers a healthcare services model with embedded workflow integration that can create durable switching costs for provider customers. The long-term thesis rests on continued digitization of patient access and care delivery operations, the ability to expand within existing accounts, and operating leverage from scaled service delivery. The primary debate for investors centers on retention/renewal durability, compliance and execution quality, and maintaining differentiation as competitors pursue similar technology-enabled service capabilities.


⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Headline (latest quarter, 2025-12-31): Revenue $1.36B and Net Income $59.7M (EPS $0.38). Revenue was up QoQ (from $1.34B) by ~+1.0%, while Net Income rose faster at ~+14.0%. Net margin improved to ~4.4% (59.7/1,358) from ~3.9% the prior quarter, indicating profitability improvement. Trend over the past 4 quarters (no prior-year quarters provided, so YoY growth rates were not computable): Revenue has been trending upward from $1.28B (2025-03-31) to $1.36B (2025-12-31). Net income was much lower in 2025-03-31 ($28.5M) but rebounded strongly through mid/late 2025, culminating in the highest quarter in the dataset. Cash flow quality weakened in the latest quarter: Free Cash Flow turned negative to about -$212M from +$286M in 2025-09-30, despite strong Operating Cash Flow in the prior quarter. Dividends were paid in the latest quarter (~$50M), with a very low reported dividend yield (~0.83%) and a high payout ratio (~0.84), suggesting dividends are supported but not yet “high-quality”/stable. Total shareholder returns look very strong: price momentum is +272.6% over 1 year, which materially boosts the total-return outlook. Analyst consensus targets imply upside (median ~$42 vs. ~$34.84 current)."

Revenue Growth

Positive

QoQ revenue rose ~+1.0% (1.357B vs. 1.345B). Over the 4-quarter run, revenue improved from ~$1.278B (2025-03-31) to ~$1.358B (2025-12-31). YoY growth rates were not computable because 2024 comparable quarters were not provided.

Profitability

Good

Net income increased ~+14.0% QoQ (59.7M vs. 52.4M). Net margin improved to ~4.4% from ~3.9%. Across the 4-quarter period, net income recovered from $28.5M (2025-03-31) to $59.7M (2025-12-31).

Cash Flow Quality

Fair

FCF deteriorated sharply in the latest quarter to about -$212M from +$286M in 2025-09-30. While earlier quarters showed solid positive FCF, the most recent quarter suggests volatility. No FCF YoY comparison possible from provided data.

Leverage & Balance Sheet

Neutral

Equity strengthened QoQ (to ~$952M from ~$877M). Total assets edged up (~$5.58B from ~$5.63B slightly down vs prior), while net debt increased QoQ (~$3.00B vs ~$2.87B), indicating modest leverage pressure.

Shareholder Returns

Strong

Strong total-return profile driven primarily by price momentum: +272.6% over 1 year. Dividend yield is low (~0.83% latest), so yield contribution is minor, but capital appreciation is very strong.

Analyst Sentiment & Valuation

Positive

Consensus median target (~$42) is above the current price (~$34.84), implying ~+20% upside. P/E is elevated in the latest quarter (~25x), consistent with investors paying for improved earnings/trajectory.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

PACS delivered record Q4 and FY25 results with strong revenue growth, rising mature-facility occupancy, and improving quality metrics, supported by a robust locally led, centrally supported operating model. The company emphasized disciplined capital allocation, maintained very low leverage, and executed targeted acquisitions while selectively increasing real estate ownership. Management’s outlook for 2026 is confident, focused on continued integration, clinical excellence, leadership development, and disciplined M&A amid favorable demographic and consolidation trends.

Growth

  • FY25 revenue up ~29% to $5.29B; Q4 revenue up ~12% to $1.36B
  • Portfolio scaled to 321 facilities across 17 states; 35,379 total operating beds (32,854 skilled nursing; 2,525 assisted living)
  • Mature-facility occupancy increased to 94.9% (up 50 bps y/y)
  • 73.4% of skilled nursing facilities rated 4–5 stars in CMS quality measures; mature average QM rating improved to 4.4 from 4.3

Business Development

  • Completed 8 strategic acquisitions in 2025 within existing markets
  • Announced January 2026 acquisition of 3 facilities (2 in Alaska with real estate; 1 in Idaho)
  • Eight de novo projects since inception; Oceanside, CA new build achieved deficiency-free initial survey and reached profitability within first year
  • Selective increase in real estate ownership to strengthen long-term alignment

Financials

  • Q4 2025: revenue $1.36B (+~12% y/y), net income $59.8M, adjusted EBITDAR $237.7M, adjusted EBITDA $142.1M
  • FY 2025: revenue $5.29B (+~29% y/y), net income $191.5M, diluted EPS $1.22, adjusted EBITDAR $883.9M, adjusted EBITDA $505.0M
  • Portfolio occupancy averaged 89.1% for FY25; ramping facilities at 86.3% (y/y decline due to cohort mix); mature facilities at 94.9%

Capital & Funding

  • Ended FY25 with net leverage of ~0.3x, supporting durability and flexibility
  • Disciplined capital allocation focused on optimizing 2024 acquisitions and selective real estate purchases
  • Willingness to invest ahead of revenue for de novos (e.g., Oceanside pre-opening investments)

Operations & Strategy

  • Locally led, centrally supported model with centralized services (accounting, compliance, HR, IT, regulatory)
  • 2025 focused on integration and performance of 2024 acquisitions, driving clinical and occupancy improvements
  • Administrator-in-Training program with 38 participants to deepen leadership bench and support growth
  • Strengthened infrastructure, systems and compliance to support scale as a public company
  • Seven zero-deficiency surveys in 2025; continued improvements in falls, pressure ulcers, medication management and discharge outcomes in highlighted facilities

Market & Outlook

  • Demographic tailwinds and fragmented industry support continued consolidation opportunity
  • 2026 priorities: integrate and optimize portfolio, invest in people and clinical capabilities, and pursue disciplined M&A with selective real estate ownership
  • Management expects continued steady reporting cadence and consistent execution

Risks Or Headwinds

  • Regulatory and compliance complexity in skilled nursing (e.g., survey rigor in states like California)
  • Ongoing integration and stabilization of recently acquired facilities; cohort mix effects on ramping occupancy
  • Exposure to hospital discharge patterns and rising patient acuity requirements

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PACS Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PACS)

© 2026 Stock Market Info — PACS Group, Inc. (PACS) Financial Profile